Multi-year analysis of the global preclinical antibacterial pipeline: trends and gaps

Antimicrobial resistance (AMR) is a significant global health threat, causing 1.27 million deaths in 2019 alone. It also has economic consequences, increasing poverty in low- and middle-income countries. To combat AMR, a continuous supply of new antibacterial medicines is needed. However, there are gaps in the current pipeline that are difficult to address. The World Health Organization regularly assesses the preclinical and clinical antibacterial development pipeline to identify potential new classes of antibiotics or novel mechanisms of action to address resistant bacterial strains. This proactive approach is crucial to stay ahead of evolving resistance patterns and support effective treatment options.